GNPX Genprex Inc

Price (delayed)

$3.42

Market cap

$2.8M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$10.5

Enterprise value

-$12.35M

?
Relative Growth: Rel. Growth: 24
Relative Strength: Rel. Strength: 0
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 5

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new ...

Highlights
The company's EPS has surged by 94% QoQ and by 91% YoY
GNPX's quick ratio is up by 20% since the previous quarter
Genprex's equity has decreased by 13% from the previous quarter

Key stats

What are the main financial stats of GNPX

GNPX stock price

How has the Genprex stock price performed over time
Intraday
-2.56%
1 week
-5.26%
1 month
-28%
1 year
-98.11%
YTD
-91.12%
QTD
-70.05%

Financial performance

How have Genprex's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$15.84M
Net income
-$16.5M
Gross margin
N/A
Net margin
N/A
The company's operating income rose by 8% YoY
The net income has grown by 4.6% year-on-year

Price vs fundamentals

How does GNPX's price correlate with its fundamentals

Growth

What is Genprex's growth rate over time

Valuation

What is Genprex stock price valuation
P/E
N/A
P/B
0.11
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The company's EPS has surged by 94% QoQ and by 91% YoY
The P/B is 95% below the 5-year quarterly average of 2.3 and 95% below the last 4 quarters average of 2.3
Genprex's equity has decreased by 13% from the previous quarter

Efficiency

How efficient is Genprex business performance
The ROE has soared by 80% YoY and by 34% QoQ
GNPX's ROA has soared by 67% YoY and by 27% from the previous quarter

Dividends

What is GNPX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for GNPX.

Financial health

How did Genprex financials performed over time
Genprex's total liabilities has decreased by 31% QoQ and by 3.9% YoY
GNPX's current ratio is up by 21% since the previous quarter
Genprex's debt is 100% lower than its equity
Genprex's equity has decreased by 13% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.